Research Paper Volume 14, Issue 22 pp 9221—9242

Comprehensive analysis of the expression profile and clinical implications of regulator of chromosome condensation 2 in pan-cancers

Xuanxuan Li1,2, , Kuo Kang3,4, , Yuanhao Peng5, , Lin Shen1, , Liangfang Shen1, , Yangying Zhou1,2, ,

  • 1 Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
  • 2 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
  • 3 Department of General Surgery, Xiangya Hospital Central South University, Changsha, Hunan 410008, China
  • 4 Hunan Key Laboratory of Precise Diagnosis and Treatment of Gastrointestinal Tumor, Xiangya Hospital Central South University, Changsha, Hunan 410008, China
  • 5 NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan 410078, China

Received: August 11, 2022       Accepted: November 16, 2022       Published: November 27, 2022
How to Cite

Copyright: © 2022 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The Regulator of Chromosome Condensation 2 (RCC2) is an important gene that regulates mitosis and cytoplasmic division in the cell cycle. Although there have been reported in several individual tumors, an integrative analysis of RCC2 and its clinical significance across diverse cancer types is poorly elucidated. In this study, we performed integrative bioinformatics analyses to profile the expression landscape and assess the prognostic value of RCC2 in pan-cancers. Correlations between RCC2 expression and tumor-infiltrating immune cells, tumor mutation burden (TMB), microsatellite instability (MSI), chemokine and their receptors were analyzed using TCGA, ESTIMATE algorithm, and TISIDB database. We also explored the potential molecular functions of RCC2 through functional enrichment analysis and protein interaction networks. We discovered that RCC2 was highly expressed in various tumor tissues and was closely associated with cancer prognosis. Different RCC2-associated immune infiltration patterns were exhibited in different tumor-infiltrating immune cells. In addition, the RCC2 had a potential role in regulating the tumor immune microenvironment and the formation of cancer-associated fibroblasts (CAFs). Meanwhile, RCC2 showed a significant correlation with TMB, MSI, chemokines and their receptors in different tumor types. The role of RCC2 as a clinical therapeutic target was further revealed from the perspective of the immune microenvironment. In conclusion, RCC2 is closely associated with tumorigenesis and cancer-immune infiltration, and could be a promising prognostic and therapeutic biomarker in diverse cancers.


ACC: Adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma; BP: Biological processes; CPC: Chromosomal passenger complex; CI: Confidence intervals; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; CAFs: Cancer-associated fibroblasts; CC: Cellular components; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; GEPIA: Gene Expression Profiling Interactive Analysis; GEF: Guanine nucleotide exchange factor; GBM: Glioblastoma multiforme; GO: Gene Ontology; HRs: Hazard ratios; HNSC: Head and neck squamous cell carcinoma; ICIs: Immune checkpoint inhibitors; IPS: immunophenoscore; KM: Kaplan-Meier; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; KICH: Kidney chromophobe; KEGG: Kyoto Encyclopedia of Genes and Genomes; LGG: Brain lower grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MSI: Microsatellite instability; MF: Molecular functions; MSI: Microsatellite instability; MESO: Mesothelioma; OS: Overall survival; OV: Ovarian serous cystadenocarcinoma; PRAD: Prostate adenocarcinoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; RCC2: Regulator Of Chromosome Condensation 2; RFS: Relapse-free survival; READ: Rectum adenocarcinoma; STAD: Stomach adenocarcinoma; SARC: Sarcoma; STES: Stomach and Esophageal carcinoma; TME: Tumor microenvironment; TCGA: The Cancer Genome Atlas; TMB: Tumor mutational burden; THCA: Thyroid carcinoma; TGCT: Testicular germ cell tumors; THYM: Thymoma; UVM: Uveal melanoma; UCEC: Uterine corpus endometrial carcinoma.